Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
|
|
12.
|
|
|
13.
|
|
|
14.
|
International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial. [electronic resource] by
- Trappe, R U
- Choquet, S
- Dierickx, D
- Mollee, P
- Zaucha, J M
- Dreyling, M H
- Dührsen, U
- Tarella, C
- Shpilberg, O
- Sender, M
- Salles, G
- Morschhauser, F
- Jaccard, A
- Lamy, T
- Reinke, P
- Neuhaus, R
- Lehmkuhl, H
- Horst, H A
- Leithäuser, M
- Schlattmann, P
- Anagnostopoulos, I
- Raphael, M
- Riess, H
- Leblond, V
- Oertel, S
Producer: 20151216
In:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons vol. 15
Availability: No items available.
|